23.29
price down icon0.09%   -0.02
pre-market  Pre-market:  23.30   0.01   +0.04%
loading
Vera Therapeutics Inc stock is traded at $23.29, with a volume of 1.97M. It is down -0.09% in the last 24 hours and up +18.58% over the past month. Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
See More
Previous Close:
$23.31
Open:
$25.06
24h Volume:
1.97M
Relative Volume:
1.25
Market Cap:
$1.44B
Revenue:
-
Net Income/Loss:
$-107.85M
P/E Ratio:
-10.54
EPS:
-2.21
Net Cash Flow:
$-106.82M
1W Performance:
+11.33%
1M Performance:
+18.58%
6M Performance:
-45.14%
1Y Performance:
-30.93%
1-Day Range:
Value
$22.75
$25.30
1-Week Range:
Value
$20.40
$25.30
52-Week Range:
Value
$18.53
$51.61

Vera Therapeutics Inc Stock (VERA) Company Profile

Name
Name
Vera Therapeutics Inc
Name
Phone
650-770-0077
Name
Address
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Name
Employee
152
Name
Twitter
Name
Next Earnings Date
2024-08-08
Name
Latest SEC Filings
Name
VERA's Discussions on Twitter

Compare VERA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VERA
Vera Therapeutics Inc
23.29 1.44B 0 -107.85M -106.82M -2.21
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades

Date Action Analyst Rating Change
May-05-25 Resumed H.C. Wainwright Buy
Feb-04-25 Initiated Wolfe Research Outperform
Jan-28-25 Initiated Goldman Buy
Nov-21-24 Initiated Wells Fargo Overweight
Oct-16-24 Initiated Scotiabank Sector Outperform
Jan-25-24 Initiated Oppenheimer Outperform
Jan-08-24 Initiated Cantor Fitzgerald Overweight
Dec-18-23 Initiated Raymond James Outperform
Nov-10-23 Upgrade Jefferies Hold → Buy
Aug-16-23 Initiated Guggenheim Buy
Jan-04-23 Downgrade Jefferies Buy → Hold
Jan-04-23 Downgrade Wedbush Outperform → Neutral
Jul-12-22 Initiated JP Morgan Overweight
May-02-22 Initiated H.C. Wainwright Buy
Apr-19-22 Initiated Wedbush Outperform
View All

Vera Therapeutics Inc Stock (VERA) Latest News

pulisher
Jun 17, 2025

Vera Therapeutics Inc put volume heavy and directionally bearish - TipRanks

Jun 17, 2025
pulisher
Jun 12, 2025

Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com

Jun 12, 2025
pulisher
Jun 11, 2025

Transcript : Vera Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 03 - marketscreener.com

Jun 11, 2025
pulisher
Jun 10, 2025

Vera Therapeutics (VERA) Sees Surge in Bullish Options Activity | VERA Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 09, 2025

Vera Therapeutics reports inducement grants under Nasdaq listing rule - MarketScreener

Jun 09, 2025
pulisher
Jun 09, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 09, 2025
pulisher
Jun 09, 2025

Vera Therapeutics Expands Team with 17 New Hires, Awards Major Stock Options Worth $6M - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

H.C. Wainwright maintains $85 target on Vera Therapeutics stock By Investing.com - Investing.com Canada

Jun 09, 2025
pulisher
Jun 09, 2025

Wedbush Cuts Price Target on Vera Therapeutics to $23 From $32, Keeps Neutral Rating - marketscreener.com

Jun 09, 2025
pulisher
Jun 08, 2025

Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Sold by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

California State Teachers Retirement System Acquires 6,749 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Vera Therapeutics (NASDAQ:VERA) Shares Gap Down – Should You Sell? - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Biotech Stocks To Watch Today – June 6th - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Otsuka’s IgAN Data Top Some Vera Results, But To What End? - insights.citeline.com

Jun 06, 2025
pulisher
Jun 06, 2025

Vera Therapeutics (VERA) Drops 32% After Trial Results Disappoin - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Vera Therapeutics (VERA) Stock Plummets Over 29% in Major Sell-Off - Daily Chhattisgarh News

Jun 06, 2025
pulisher
Jun 06, 2025

Biotech Stock Vera Is Slumping After Monster Gain - Barron's

Jun 06, 2025
pulisher
Jun 06, 2025

Vera Therapeutics stock sinks following competitor’s successful trial By Investing.com - Investing.com Nigeria

Jun 06, 2025
pulisher
Jun 06, 2025

Vera Therapeutics stock sinks following competitor’s successful trial - Investing.com Australia

Jun 06, 2025
pulisher
Jun 06, 2025

Vera stock drops as Otsuka bests with IgAN drug (VERA:NASDAQ) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Bank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Research Analysts Offer Predictions for VERA FY2027 Earnings - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail

Jun 06, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Scotiabank Increases the Price Target for Vera Therapeutics by $10 - MSN

Jun 05, 2025
pulisher
Jun 05, 2025

FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

(VERA) Trading Advice - news.stocktradersdaily.com

Jun 05, 2025
pulisher
Jun 05, 2025

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire

Jun 05, 2025
pulisher
Jun 04, 2025

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Clinical-Stage Biotech Vera Therapeutics Joins Elite Goldman Sachs Healthcare Conference Lineup - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

Latham & Watkins Advises Vera Therapeutics in US$500 Million Credit Facility With Oxford Finance - Latham & Watkins LLP

Jun 04, 2025
pulisher
Jun 04, 2025

Vera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Equities Analysts Set Expectations for VERA Q2 Earnings - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Vera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst Upgrade - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Vera Therapeutics eyes half billion dollars after kidney drug study - The Business Journals

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (VERA) Price Target Increased Amid Positive Tr - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40 By Stocktwits - Investing.com India

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (VERA) Secures $500 Million Credit Facility - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (VERA) Sees Price Target Boost Following Positive Trial Results | VERA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics Secures $500M Loan Agreement - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 ... - Bluefield Daily Telegraph

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics Lands Massive $500M Financing Deal as FDA Filing for Kidney Drug Approaches - Stock Titan

Jun 03, 2025
pulisher
Jun 03, 2025

Two Sigma Investments LP Sells 7,102 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (NASDAQ:VERA) PT Set at $65.00 by Scotiabank - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (NASDAQ:VERA) Given New $85.00 Price Target at HC Wainwright - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Vera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst Upgrade - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Vera Therapeutics: Primary endpoint was met in ORIGIN Phase 3 trial of atacicept - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

H.C. Wainwright ups Vera Therapeutics target on ‘home run’ data - TipRanks

Jun 02, 2025

Vera Therapeutics Inc Stock (VERA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Vera Therapeutics Inc Stock (VERA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
ENRIGHT PATRICK G
Director
Jun 24 '25
Buy
22.35
40,607
907,635
3,596,593
Fordyce Marshall
PRESIDENT AND CEO
Feb 21 '25
Sale
27.89
10,613
296,032
213,740
Fordyce Marshall
PRESIDENT AND CEO
Feb 26 '25
Sale
27.65
9,075
250,882
204,665
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Cap:     |  Volume (24h):